Lilly’s Late-Stage CNS Pipeline Bare Following Edivoxetine Failure
Depression candidate edivoxetine fails in three Phase III studies, marking a third recent blow to Lilly’s neuroscience pipeline efforts.
Depression candidate edivoxetine fails in three Phase III studies, marking a third recent blow to Lilly’s neuroscience pipeline efforts.